Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Biosimilars Workshop: Second Time’s The Charm?

This article was originally published in The Pink Sheet Daily

Executive Summary

Having failed to significantly influence the design of the federal approval pathway, the Commission is hoping to have an impact on product naming and state substitution laws.

You may also be interested in...



FDA’s Purple Book Launches Categorization Era For Biosimilars

Modeled on “Orange Book” reference guide for small molecule drugs, agency’s new publication will be a repository of exclusivity and interchangeability information.

Biosimilar Naming Fight: Could Brand Names For All Resolve The Problem?

Brand and generic drug companies continued their debate on distinguishable INNs for biosimilars during a Federal Trade Commission meeting Feb. 4.

Biologics To Get Orange Book-style Reference Guide

Color remains a mystery, but publication may come in handy soon as biosimilar sponsors are nearing the marketing application stage.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel